The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex - PubMed (original) (raw)
. 2002 Nov 22;277(47):45162-71.
doi: 10.1074/jbc.M206882200. Epub 2002 Sep 4.
Affiliations
- PMID: 12215447
- DOI: 10.1074/jbc.M206882200
Free article
The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex
Olivier Micheau et al. J Biol Chem. 2002.
Free article
Abstract
Death receptors, such as Fas and tumor necrosis factor-related apoptosis-inducing ligand receptors, recruit Fas-associated death domain and pro-caspase-8 homodimers, which are then autoproteolytically activated. Active caspase-8 is released into the cytoplasm, where it cleaves various proteins including pro-caspase-3, resulting in apoptosis. The cellular Fas-associated death domain-like interleukin-1-beta-converting enzyme-inhibitory protein long form (FLIP(L)), a structural homologue of caspase-8 lacking caspase activity because of several mutations in the active site, is a potent inhibitor of death receptor-induced apoptosis. FLIP(L) is proposed to block caspase-8 activity by forming a proteolytically inactive heterodimer with caspase-8. In contrast, we propose that FLIP(L)-bound caspase-8 is an active protease. Upon heterocomplex formation, a limited caspase-8 autoprocessing occurs resulting in the generation of the p43/41 and the p12 subunits. This partially processed form but also the non-cleaved FLIP(L)-caspase-8 heterocomplex are proteolytically active because they both bind synthetic substrates efficiently. Moreover, FLIP(L) expression favors receptor-interacting kinase (RIP) processing within the Fas-signaling complex. We propose that FLIP(L) inhibits caspase-8 release-dependent pro-apoptotic signals, whereas the single, membrane-restricted active site of the FLIP(L)-caspase-8 heterocomplex is proteolytically active and acts on local substrates such as RIP.
Similar articles
- Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway.
Siegmund D, Mauri D, Peters N, Juo P, Thome M, Reichwein M, Blenis J, Scheurich P, Tschopp J, Wajant H. Siegmund D, et al. J Biol Chem. 2001 Aug 31;276(35):32585-90. doi: 10.1074/jbc.M100444200. Epub 2001 May 30. J Biol Chem. 2001. PMID: 11384965 - Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells.
Hennino A, Berard M, Casamayor-Pallejà M, Krammer PH, Defrance T. Hennino A, et al. J Immunol. 2000 Sep 15;165(6):3023-30. doi: 10.4049/jimmunol.165.6.3023. J Immunol. 2000. PMID: 10975811 - N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway.
Kataoka T, Tschopp J. Kataoka T, et al. Mol Cell Biol. 2004 Apr;24(7):2627-36. doi: 10.1128/MCB.24.7.2627-2636.2004. Mol Cell Biol. 2004. PMID: 15024054 Free PMC article. - Death receptor-induced cell killing.
Thorburn A. Thorburn A. Cell Signal. 2004 Feb;16(2):139-44. doi: 10.1016/j.cellsig.2003.08.007. Cell Signal. 2004. PMID: 14636884 Review. - Regulation of CD95/Fas signaling at the DISC.
Lavrik IN, Krammer PH. Lavrik IN, et al. Cell Death Differ. 2012 Jan;19(1):36-41. doi: 10.1038/cdd.2011.155. Epub 2011 Nov 11. Cell Death Differ. 2012. PMID: 22075988 Free PMC article. Review.
Cited by
- Targeting caspase-8/c-FLIPL heterodimer in complex II promotes DL-mediated cell death.
Hillert-Richter LK, König C, Ivanisenko NV, Reinhold D, Lavrik IN. Hillert-Richter LK, et al. Front Cell Dev Biol. 2024 Sep 30;12:1471216. doi: 10.3389/fcell.2024.1471216. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39403127 Free PMC article. - Caspase-8 in inflammatory diseases: a potential therapeutic target.
Zhang W, Zhu C, Liao Y, Zhou M, Xu W, Zou Z. Zhang W, et al. Cell Mol Biol Lett. 2024 Oct 8;29(1):130. doi: 10.1186/s11658-024-00646-x. Cell Mol Biol Lett. 2024. PMID: 39379817 Free PMC article. Review. - TRAIL C1595T Variant Critically Alters the Level of sTRAIL in Terms of Histopathological Parameters in Colorectal Cancer.
Horozoglu C, Yildiz A, Sonmez D, Demirkol S, Yildiz Y, Arikan S, Yaylim I. Horozoglu C, et al. Indian J Clin Biochem. 2024 Oct;39(4):593-599. doi: 10.1007/s12291-023-01146-z. Epub 2023 Aug 9. Indian J Clin Biochem. 2024. PMID: 39346710 - Allicin: a promising modulator of apoptosis and survival signaling in cancer.
Bhuker S, Kaur A, Rajauria K, Tuli HS, Saini AK, Saini RV, Gupta M. Bhuker S, et al. Med Oncol. 2024 Jul 26;41(9):210. doi: 10.1007/s12032-024-02459-6. Med Oncol. 2024. PMID: 39060753 Review. - Targeting apoptotic pathways for cancer therapy.
Tian X, Srinivasan PR, Tajiknia V, Sanchez Sevilla Uruchurtu AF, Seyhan AA, Carneiro BA, De La Cruz A, Pinho-Schwermann M, George A, Zhao S, Strandberg J, Di Cristofano F, Zhang S, Zhou L, Raufi AG, Navaraj A, Zhang Y, Verovkina N, Ghandali M, Ryspayeva D, El-Deiry WS. Tian X, et al. J Clin Invest. 2024 Jul 15;134(14):e179570. doi: 10.1172/JCI179570. J Clin Invest. 2024. PMID: 39007268 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous